Search Results
Your search for all items matches 34736 pages
Showing 15851 - 15900Artificial Intelligence vs Radiologists in Breast Cancer Detection With Digital Mammography
In a study reported in the Journal of the National Cancer Institute, Rodriguez-Ruiz et al found that a stand-alone artificial intelligence (AI) system had accuracy comparable to an average breast radiologist in detecting breast cancer using digital mammography. Study Details In the retrospective...
Therapy-Related Cardiac Disease Risk in Childhood Cancer Survivors
As reported by Bates et al in the Journal of Clinical Oncology, an analysis from the Childhood Cancer Survivor Study indicated that radiation doses in conjunction with heart volume exposed to radiation and anthracycline treatment were associated with increased risk of late-onset cardiac disease in...
Immunotherapy Directed Against Precancerous Skin Lesions May Prevent Squamous Cell Carcinoma
A treatment previously shown to treat the precancerous skin lesions called actinic keratosis now appears to also reduce the chance that these pretreated lesions will develop into squamous cell carcinoma. In a report published by Rosenberg et al in JCI Insight, researchers found that treatment with...
FDA Pipeline: Safety Warning About Investigational Use of Venetoclax in Multiple Myeloma, Warning Letter on Unapproved Products
This week, the U.S. Food and Drug Administration (FDA) posted a safety statement on the investigational use of venetoclax in multiple myeloma, and also posted a warning letter against a company for illegally marketing unapproved products labeled as homeopathic. Safety Statement The FDA posted...
Melinda L. Telli, MD, on NCCN Guidelines Updates for HR-Positive, HER2-Negative Early-Stage Breast Cancer
Melinda L. Telli, MD, of the Stanford Cancer Institute, discusses the various systemic therapies for patients with early-stage hormone receptor–positive, HER2-negative disease.
Eric Jonasch, MD, on Kidney Cancer: A Year in Review
Eric Jonasch, MD, of The University of Texas MD Anderson Cancer Center, discusses major findings over the past 12 months in kidney cancer, including combination immunotherapies and trends in surgical oncology.
Matthew A. Gubens, MD, on Non–Small Cell Lung Cancer: New Immunotherapy Strategies in the NCCN Guidelines
Matthew A. Gubens, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discusses recent updates to the NCCN Guidelines in non–small cell lung cancer, including the use of pembrolizumab as a single agent or in combination based on PD-L1 status, treatment selection in squamous and...
William J. Gradishar, MD, on HR-Positive, HER2-Negative Advanced Breast Cancer: NCCN Guidelines Updates
William J. Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses evidence-based first-line treatment options for patients with advanced hormone receptor–positive, HER2-negative breast cancer and toxicities associated with the various therapeutic...
Frederick L. Locke, MD, on Innovative CAR-T Cell Therapies: The Patient Experience
Frederick L. Locke, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discusses recent approvals of chimeric antigen receptor T-cell therapies in leukemia and lymphoma, and how clinicians are using infrastructure, navigation, and early referrals to maximize response and minimize...
Does Minimally Invasive Robotic Surgery for Early-Stage Endometrial Cancer Decrease the Risk of Surgical Complications?
In a Danish study reported in JAMA Surgery, Jørgensen et al found that the nationwide introduction of minimally invasive robotic surgery for early-stage endometrial cancer was associated with a reduction in the incidence of severe complications. The nationwide prospective cohort study...
Effect of Microsatellite Instability and Tumor Mutational Burden on Outcome in First-Line Treatment of Metastatic Colorectal Cancer
In an analysis of the phase III CALGB/SWOG 80405 trial reported in the Journal of Clinical Oncology, Innocenti et al found that tumor mutational burden and microsatellite instability status affected overall survival in patients receiving first-line chemotherapy plus bevacizumab or cetuximab for...
Validation Study of Several Models of Breast Cancer Risk
In a validation study reported in The Lancet Oncology, Terry et al found that the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm model (BOADICEA) and the International Breast Cancer Intervention Study model (IBIS) were the best of 4 models tested for predicting...
Persistent Long-Term Fatigue and Impact on Quality of Life Among Epithelial Ovarian Cancer Survivors
A study among epithelial ovarian cancer survivors from 25 cooperative Gynecologic Cancer Intergroup centers in France showed similar quality of life compared to healthy controls who were randomly selected from the electoral rolls, but persistent long-term fatigue. The researchers found depression,...
Infertility in Women and Low Absolute Risk of Cancer
A study of over 64,000 women of childbearing age in the United States has found that infertility is associated with a higher risk of developing cancer compared to a group of over 3 million women without fertility problems—although the absolute risk is very low, at just 2%. These findings ...
Number of Pregnancies May Influence Breast Cancer Risk in Women With BRCA Mutations
Researchers have found the lower risk of breast cancer associated with multiple pregnancies and breastfeeding in the general population extends to those at the highest risk of breast cancer. These results were published by Terry et al in the JNCI Cancer Spectrum. Methods and Findings The...
Demographic Factors Increasing Risk of Liver Cancer Development in Patients With Fatty Liver Disease
A new study published by Zarrinpar et al in Liver International has found that elderly, diabetic, and Hispanic patients with steatohepatitis—fatty liver disease—may have a higher risk of developing liver cancer. Ali Zarrinpar, MD, PhD, Associate Professor of Surgery at the...
AR-V7 Assay Findings and Outcomes With Hormone Therapy in High-Risk Castration-Resistant Prostate Cancer
In the PROPHECY study, reported in the Journal of Clinical Oncology, Armstrong et al found that positive findings on 2 assays for circulating tumor cell (CTC) androgen receptor splice variant 7 (AR-V7) were associated with poorer outcomes for abiraterone and enzalutamide therapy in men with...
Effect of Medical Cannabis on Symptom Control in Patients With Cancer
As reported in the Journal of Oncology Practice by Anderson et al, a study of patients enrolled in Minnesota’s Medical Cannabis Program showed that the use of medical cannabis was associated with improvement in reported symptoms in patients with cancer. The study involved data on 1,120...
Neratinib Plus Capecitabine Active Against HER2-Positive Breast Cancer Brain Metastases
In the phase II TBCRC 022 trial reported in the Journal of Clinical Oncology, Freedman et al found that the combination of neratinib and capecitabine was active against brain metastases in women with HER2-positive breast cancer. Modest activity of neratinib monotherapy had been found in previous...
Jyoti D. Patel, MD, on Stage III Non–Small Cell Lung Cancer: A Look at New Systemic Treatments
Jyoti D. Patel, MD, of the University of Chicago, discusses immunotherapy for locally advanced NSCLC, selecting patients for these treatments, and the potential toxicities of combination therapies.
Susan Y. Wu, MD, on Non–Small Cell Lung Cancer: Using an Online Tool in Treatment
Susan Y. Wu, MD, of the University of California, San Francisco, discusses how patient exposure to treatment guidelines improved smoking cessation counseling and the use of molecular testing, and decreased the use of adjuvant chemotherapy in patients with early-stage disease (Abstract 5).
Mark K. Ferguson, MD, on Mitigating Frailty and Sarcopenia to Improve Treatment Outcomes
Mark K. Ferguson, MD, of the University of Chicago Hospital, discusses frailty and loss of muscle tissue, which are common among patients with lung cancer. These conditions are linked with decreased survival as well as increased surgical complications, chemotherapy toxicity, and cost of care.
Jing Zeng, MD, on Non–Small Cell Lung Cancer: Therapeutic Implications of Proper Disease Staging
Jing Zeng, MD, of the University of Washington, discusses upstaging disease from stage III to stage IV, which can occur with repeat PET and/or CT scans for patients with locally advanced NSCLC, and the need for clinicians to stage disease properly to ensure appropriate treatment.
Martin Edelman, MD, on Immunotherapy: How Safe Is It for Patients With Autoimmune Disease?
Martin Edelman, MD, of Fox Chase Cancer Center, discusses the limited retrospective data that indicate some patients with cancer and autoimmune disease (such as lupus or ulcerative colitis) can safely receive immunotherapy with checkpoint inhibitors.
Ruqin Chen, MB, on Lung Cancer Treated With Immune Checkpoint Inhibitors: Survival Outcomes and Clinical and Molecular Features
Ruqin Chen, MB, of the Mayo Clinic Florida, discusses early study findings that show molecular profiling with NF1, CD79a, and AKT3 could potentially improve prediction of progression-free survival in patients with lung cancer who are receiving immunotherapy.
Kyle F. Concannon, MD, on Lung Cancer in Homeless Patients: Outcomes and Quality Measures
Kyle F. Concannon, MD, of the University of Washington/Seattle Cancer Care Alliance, discusses study results on the delays in biopsy after radiographic findings among homeless vs housed patients with lung cancer, and the higher rates of missed appointments following diagnosis (Abstract 125).
J. Fletcher Drogos, MD, on Multiple Courses of Stereotactic Body Radiation Therapy: Outcomes in Patients With Lung Cancer
J. Fletcher Drogos, MD, of Rush University, discusses study findings on overall survival and toxicity among patients who undergo multiple radiation treatments for lung cancer.
Shraddha M. Dalwadi, MD, MBA, on Non–Small Cell Lung Cancer: What Contributes to Disparities in Treating Stage I Disease
Shraddha M. Dalwadi, MD, MBA, of Baylor College of Medicine, discusses the nearly 12% of potentially curable patients with stage I NSCLC who do not receive treatment, the various socioeconomic reasons why, and how some patients may benefit from minimally invasive therapies (Abstract 127).
Aaron S. Mansfield, MD, on Treating Rare Thoracic Cancers: Status Update
Aaron S. Mansfield, MD, of the Mayo Clinic, summarizes a session he moderated on rare thoracic cancers such as mesothelioma and thymic epithelial tumors, as well as novel imaging and treatments in neuroendocrine tumors.
Heather A. Wakelee, MD, on Advanced Non–Small Cell Lung Cancer: State-of-the-Art Treatment for EGFR-Positive and ALK-Positive Diseases
Heather A. Wakelee, MD, of Stanford University, discusses the most recent FDA-approved tyrosine kinase inhibitors that target EGFR and ALK mutations, how these agents fit into the treatment landscape, and the rapidly evolving field of TKI resistance.
Leora Horn, MD, on Small Cell Lung Cancer and Immuno-oncology: Have We Finally Solved the Small Cell Paradox?
Leora Horn, MD, of Vanderbilt University Medical Center, discusses the progress made treating extensive-stage small cell lung cancer, improvements in progression-free and overall survival, and the fact that it’s still difficult to determine which patients will benefit most from immunotherapy.
SGO 2019: Post Hoc Exploratory Analyses From the ARIEL3 Trial in Recurrent Ovarian Cancer
Data from post hoc exploratory analyses from the phase III ARIEL3 clinical study of rucaparib in recurrent ovarian cancer was presented during oral plenary and poster sessions at the Society of Gynecologic Oncology’s (SGO) 50th Annual Meeting on Women’s Cancer. These analyses...
Coming In Future Issues of The ASCO Post
Watch upcoming issues of The ASCO Post for news reports from the 2019 Multidisciplinary Thoracic Cancers Symposium, taking place March 14-16, 2019, in San Diego. Watch for reports on these presentations, plus much more. “Improved Overall Survival with Local Consolidative Therapy in...
President’s FY2020 Budget Threatens Progress Against Cancer, Patient Access to Care
“We strongly oppose the White House budget proposal for Fiscal Year (FY) 2020, which would stall our nation’s progress against cancer and impede access to needed care for the millions of Americans dealing with cancer. The proposal would make drastic, unprecedented cuts to the U.S. Department of...
Intracranial Malignancy After Stereotactic Radiosurgery for Nonmalignant Conditions
In a retrospective cohort study reported in The Lancet Oncology, Douglas Kondziolka, MD, of NYU Langone Health System, and colleagues found that patients undergoing Gamma Knife stereotactic radiosurgery for nonmalignant neurosurgical conditions did not appear to be at long-term increased risk of...
SGO 2019: Dendritic Cell–Based Immunotherapy in Combination With Chemotherapy in Recurrent Ovarian Cancer
Results from a clinical trial presented by Cibula et al at the Society of Gynecologic Oncology’s (SGO) 50th Annual Meeting on Women’s Cancer showed that a new immunotherapy treatment significantly prolongs survival in women with recurrent ovarian cancer when added to standard...
Docetaxel Plus Androgen-Deprivation Therapy After Primary Local Therapy in High-Risk Prostate Cancer
In a French phase III trial reported in JAMA Oncology, Stéphane Oudard, MD, PhD, of Hôpital Européen Georges Pompidou, and colleagues found that the addition of docetaxel to androgen-deprivation therapy (ADT) did not improve prostate-specific antigen (PSA) progression-free survival in men with...
Patient-Reported Outcomes With Enzalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer
As reported by Bertrand Tombal, MD, of the Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, and colleagues in The Lancet Oncology, treatment with enzalutamide was associated with clinically meaningful delays in pain progression, symptom worsening, and deterioration in...
SGO 2019: Treatment With Maintenance Niraparib in Recurrent Ovarian Cancer Extends Time Without Symptoms or Toxicity
Findings from a recent clinical trial presented in a Scientific Plenary session at the Society of Gynecologic Oncology’s (SGO) 50th Annual Meeting on Women’s Cancer revealed that women with recurrent ovarian cancer who received niraparib as maintenance therapy experienced more time...
Use Technology and Appreciate the Importance of Partners
Most oncologists are comfortable treating lesbian, gay, bisexual, transgender, and queer/questioning (LGBTQ) patients with cancer, according to a survey of 149 oncologists from 45 National Cancer Institute–designated Comprehensive Cancer Centers, but not as confident in their knowledge of the...
Knowing Gender Identity and Sexual Orientation of Patients Is a Vital Aspect of Medical Care
A survey of oncologists from National Cancer Institute (NCI)-designated Comprehensive Cancer Centers found that 95.3% of oncologists who responded are comfortable with treating lesbian, gay, and bisexual patients with cancer, and 82.5% are comfortable treating transgender patients with cancer.1...
Restarting My Life After Terminal Cancer
At the end of 2015, I was dying. I was just 50 years old and a wife and mother of 2 teenage boys. Twelve years earlier, I had been diagnosed with ductal carcinoma in situ in my left breast. Despite a modified radical mastectomy and removal of nearly all of the lymph nodes in my left underarm—which ...
Obesity, Examined and Explained
BOOKMARK Title: The Obesity Code: Unlocking the Secrets of Weight LossAuthor: Jason Fung, MDPublisher: Greystone BooksDate: March 2016Price: $18.95, paperback; 296 pages According to data from the National Cancer Institute (NCI), obesity plays a significant role in developing at least 12 different ...
SGO 2019: Brachytherapy Boost Added to EBRT and Chemotherapy in Advanced Cervical Cancer
A recent National Cancer Database study has shown the current standard of care for advanced cervical cancer—external-beam radiation and chemotherapy in combination with brachytherapy—provides significantly higher overall survival over chemoradiation alone. However, the addition of...
New England Cancer Specialists to Join Dana-Farber Cancer Care Collaborative
The Dana-Farber Cancer Institute announced recently that New England Cancer Specialists is the newest member of the Dana-Farber Cancer Care Collaborative. Participation in the Collaborative reflects a demonstrated commitment to excellence by meeting a wide array of standards and best practices....
Royal Swedish Academy of Sciences Accepting Candidates for Sjöberg Prize 2020
The Royal Swedish Academy of Sciences is accepting candidate nominations for The Sjöberg Prize 2020. The Sjöberg Prize for Cancer Research is awarded to scientists who have made major contributions to our knowledge about disease mechanisms, risk factors, or the treatment or prevention of cancer....
SGO 2019: HPV Vaccine Uptake in the Deep South
A study by Pierce et al presented at the Society of Gynecologic Oncology’s (SGO) 50th Annual Meeting on Women’s Cancer showed that human papillomavirus (HPV) vaccination rates in Alabama are highest in counties with high incidence rates of HPV-related cancer (Abstract 13). ...
Florida Cancer Specialists Welcomes Nalini Hasija, MD
Florida Cancer Specialists & Research Institute have announced that medical oncologist/hematologist Nalini Hasija, MD, has joined the statewide practice, which encompasses a network of nearly 100 locations. Dr. Hasija will be seeing patients at the Tampa Cancer Center. Professional Training Dr. ...
Sweet Surrender
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
WebMD Recognizes Seven Cancer Innovators With Its Health Heroes Award
On January 15, 2019, WebMD, an online and print health-care resource for consumers, presented its 2018 Health Heroes Award in New York City to 7 people who are making a difference in oncology care. The honorees include Karen M. Winkfield, MD, PhD, Associate Professor of Radiation Oncology at Wake...
